Display options
Cite
Osgood CL, Tantawy MN, Maloney N, et al. . Sci Rep. 2016;6:33926doi: 10.1038/srep33926.
Osgood, C. L., Tantawy, M. N., Maloney, N., Madaj, Z. B., Peck, A., Boguslawski, E., Jess, J., Buck, J., Winn, M. E., Manning, H. C., & Grohar, P. J. (2016). . Scientific reports, 633926. https://doi.org/10.1038/srep33926
Osgood, Christy L, et al. "." Scientific reports vol. 6 (2016): 33926. doi: https://doi.org/10.1038/srep33926
Osgood CL, Tantawy MN, Maloney N, Madaj ZB, Peck A, Boguslawski E, Jess J, Buck J, Winn ME, Manning HC, Grohar PJ. . Sci Rep. 2016 Sep 27;6:33926. doi: 10.1038/srep33926. PMID: 27671553; PMCID: PMC5037393.
Copy Download .nbib Format: NLM
Share it on

Sci Rep. 2016 Sep 27;6:33926. doi: 10.1038/srep33926.

[No title available]

Scientific reports

Christy L Osgood, Mohammed N Tantawy, Nichole Maloney, Zachary B Madaj, Anderson Peck, Elissa Boguslawski, Jennifer Jess, Jason Buck, Mary E Winn, H Charles Manning, Patrick J Grohar

Affiliations

  1. Division of Pediatric Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, TN, USA.
  2. Vanderbilt University Institute of Imaging Science, USA.
  3. Van Andel Research Institute, Grand Rapids, MI, USA.
  4. Helen De Vos Children's Hospital, Grand Rapids, MI, USA.
  5. Michigan State University School of Medicine, Department of Pediatrics, MI, USA.

PMID: 27671553 PMCID: PMC5037393 DOI: 10.1038/srep33926

Abstract

Ewing sarcoma is a bone and soft-tissue tumor that depends on the activity of the EWS-FLI1 transcription factor for cell survival. Although a number of compounds have been shown to inhibit EWS-FLI1 in vitro, a clinical EWS-FLI1-directed therapy has not been achieved. One problem plaguing drug development efforts is the lack of a suitable, non-invasive, pharmacodynamic marker of EWS-FLI1 activity. Here we show that

References

  1. Eur J Cell Biol. 2009 Dec;88(12):779-85 - PubMed
  2. Eur J Cancer. 2016 Mar;55:81-97 - PubMed
  3. PLoS One. 2013 Jul 22;8(7):e69714 - PubMed
  4. Clin Cancer Res. 2014 Mar 1;20(5):1190-203 - PubMed
  5. PLoS Med. 2007 Apr;4(4):e122 - PubMed
  6. Biochem Pharmacol. 2010 Nov 15;80(10):1528-36 - PubMed
  7. Anal Cell Pathol. 2001;23(1):11-9 - PubMed
  8. PLoS One. 2009;4(4):e5415 - PubMed
  9. Int J Cancer. 2012 Nov 1;131(9):2153-64 - PubMed
  10. Nat Med. 2009 Jul;15(7):750-6 - PubMed
  11. Genome Res. 2013 Nov;23 (11):1797-809 - PubMed
  12. Cancer Res. 2003 Jul 15;63(14):4268-74 - PubMed
  13. PLoS One. 2014 Sep 23;9(9):e108193 - PubMed
  14. Eur J Cancer. 2012 Dec;48(18):3499-513 - PubMed
  15. J Natl Cancer Inst. 2011 Jun 22;103(12):962-78 - PubMed
  16. Eur J Cancer. 2012 Mar;48(4):579-85 - PubMed
  17. Cancer Res. 2003 May 15;63(10 ):2681-7 - PubMed
  18. PLoS Genet. 2014 Jul 10;10(7):e1004475 - PubMed
  19. J Nucl Med. 2013 Mar;54(3):424-30 - PubMed
  20. Expert Opin Ther Targets. 2005 Aug;9(4):825-30 - PubMed
  21. J Nucl Med. 2002 Sep;43(9):1210-7 - PubMed
  22. Nucl Med Biol. 2004 Oct;31(7):829-37 - PubMed
  23. Clin Cancer Res. 2012 Mar 1;18(5):1303-12 - PubMed
  24. Cancer Discov. 2014 Nov;4(11):1326-41 - PubMed
  25. Pediatr Blood Cancer. 2009 Mar;52(3):324-7 - PubMed
  26. Clin Cancer Res. 2016 Aug 15;22(16):4105-18 - PubMed
  27. Sarcoma. 2011;2011:598704 - PubMed
  28. Mol Ther. 2003 Jun;7(6):811-6 - PubMed
  29. Appl Radiat Isot. 2015 Mar;97:47-51 - PubMed
  30. Cancer Discov. 2014 Nov;4(11):1342-53 - PubMed
  31. Nucl Med Commun. 2015 Jul;36(7):695-701 - PubMed
  32. Mol Pharmacol. 2008 Nov;74(5):1372-80 - PubMed
  33. Nature. 1992 Sep 10;359(6391):162-5 - PubMed
  34. Neoplasia. 2011 Feb;13(2):145-53 - PubMed
  35. Am J Nucl Med Mol Imaging. 2015 Oct 12;5(5):431-56 - PubMed
  36. Nat Med. 1998 Nov;4(11):1334-6 - PubMed

Publication Types

Grant support